Paper · 32449510
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T and 22 others. Carcinogenesis, 2021. Cited by 33 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. Papers, record 32449510. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32449510
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Neoplastic Stem Cells | Major topic |
| Phenylurea Compounds | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Quinolines | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Female | |
| Fibroblast Growth Factor 2 | |
| Fibroblast Growth Factors | |
| Fluorouracil | |
| Humans | |
| Mice | |
| Molecular Targeted Therapy | |
| Receptor, Fibroblast Growth Factor, Type 1 | |
| Receptor, Fibroblast Growth Factor, Type 2 | |
| Receptor, Fibroblast Growth Factor, Type 3 | |
| Receptor, Fibroblast Growth Factor, Type 4 | |
| Signal Transduction | |
| Sorafenib | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,328,861 | Clinicopathologic and prognostic significance of TIAM2 overexpression in resected hepatocellular carcinoma. | Future Sci OA | 2025 | https://conductscience.org/library/papers/41328861 | PubMed |
| 41,226,200 | Protein-Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection. | Molecules | 2025 | https://conductscience.org/library/papers/41226200 | PubMed |
| 40,242,310 | Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC. | JHEP Rep | 2025 | https://conductscience.org/library/papers/40242310 | PubMed |
| 39,961,903 | Molecular subtyping combined with multiomics analysis to study correlation between TACE refractoriness and tumor stemness in hepatocellular carcinoma. | Discov Oncol | 2025 | https://conductscience.org/library/papers/39961903 | PubMed |
| 39,958,920 | Current status and new directions for hepatocellular carcinoma diagnosis. | Liver Res | 2024 | https://conductscience.org/library/papers/39958920 | PubMed |
| 39,709,431 | Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/39709431 | PubMed |
| 39,113,358 | Small-molecule-based targeted therapy in liver cancer. | Mol Ther | 2024 | https://conductscience.org/library/papers/39113358 | PubMed |
| 39,060,914 | Targeting Hepatic Cancer Stem Cells (CSCs) and Related Drug Resistance by Small Interfering RNA (siRNA). | Cell Biochem Biophys | 2024 | https://conductscience.org/library/papers/39060914 | PubMed |
| 38,927,059 | Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments-An Overview. | Biomolecules | 2024 | https://conductscience.org/library/papers/38927059 | PubMed |
| 38,867,242 | Targeted silencing of SOCS1 by DNMT1 promotes stemness of human liver cancer stem-like cells. | Cancer Cell Int | 2024 | https://conductscience.org/library/papers/38867242 | PubMed |
1 to 10 of 29
See all 29 cited byGenes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD44 | 960 | PubTator's text mining | https://conductscience.org/library/genes/960 | NCBI Gene |
| FGFR1 | 2,260 | PubTator's text mining | https://conductscience.org/library/genes/2260 | NCBI Gene |
| FGFR2 | 2,263 | PubTator's text mining | https://conductscience.org/library/genes/2263 | NCBI Gene |
| FGFR3 | 2,261 | PubTator's text mining | https://conductscience.org/library/genes/2261 | NCBI Gene |
| FGFR4 | 2,264 | PubTator's text mining | https://conductscience.org/library/genes/2264 | NCBI Gene |
| PROM1 | 8,842 | PubTator's text mining | https://conductscience.org/library/genes/8842 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32449510
GET https://conductscience.org/api/papers/v1/32449510/authors?page=2